Vaccine (DNA plasmid) · Immune activation, directed at avian influenza virus antigen · developed by INOVIO PHARMACEUTICALS
INO-3401 is a DNA plasmid vaccine studied in healthy subjects for prevention of avian influenza.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01403155 | Phase 1 | Healthy | Completed | INO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy
Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.
See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INO catalysts and pipeline →